There are some challenging things to consider and research for CAR-T:
- The high cost
https://www.webmd.com/cancer/lymphoma/features/navigate-finances-car-t-cell-therapy- Complexity of treatment administration (the greater the complexity, logically the greater the risk, complexity increases cost of trials and so on)
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy- The saturation of the market (the large number of treatments being developed) makes it hard for new products to secure market share
- Response rates in solid tumours have been limited and there have been significant safety hurdles
https://www.mdpi.com/2072-6694/14/23/5983
General Comments / Chat, page-7522
-
- There are more pages in this discussion • 4,426 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |